切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (02) : 155 -157. doi: 10.3877/cma.j.issn.1674-3946.2020.02.015

所属专题: 文献

论著

新辅助化疗对低位直肠癌化疗疗效及手术效果的影响
高树全1,(), 薛军1, 张迎春1, 崔大鹏1, 范露露1, 刘振显1   
  1. 1. 075000 河北张家口,河北北方学院附属第一医院肝胆外科
  • 收稿日期:2019-04-27 出版日期:2020-04-26
  • 通信作者: 高树全

Effect of neoadjuvant chemotherapy on chemotherapy and Clinical outcome of low rectal cancer surgery combined with neoadjuvant chemotherapy

Shuquan Gao1,(), Jun Xue1, Yingchun Zhang1, Dapeng Cui1, Lulu Fan1, Zhenxian Liu1   

  1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital of Hebei North University, Hebei 075000, China
  • Received:2019-04-27 Published:2020-04-26
  • Corresponding author: Shuquan Gao
  • About author:
    Corresponding author: Gao Shuquan , Email:
  • Supported by:
    Scientific research Fundation of Hebei Provincial Department of Health(No.20180813)
引用本文:

高树全, 薛军, 张迎春, 崔大鹏, 范露露, 刘振显. 新辅助化疗对低位直肠癌化疗疗效及手术效果的影响[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(02): 155-157.

Shuquan Gao, Jun Xue, Yingchun Zhang, Dapeng Cui, Lulu Fan, Zhenxian Liu. Effect of neoadjuvant chemotherapy on chemotherapy and Clinical outcome of low rectal cancer surgery combined with neoadjuvant chemotherapy[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(02): 155-157.

目的

探讨规范化新辅助化疗(NC)治疗低位直肠癌的化疗疗效及对手术效果的影响。

方法

选取2016年10月至2018年10月接受治疗的96例低位直肠癌患者为研究对象,按照随机数表分为两组,开腹组行开腹手术治疗,NC组术前添加规范化NC,治疗后行开腹手术,各48例。采用SPSS23.0软件对数据进行统计学分析。术中术后指标采用(±s)描述,采用独立t检验;术后并发症发生率比较采用χ2检验,P<0.05为差异有统计学意义。

结果

NC组淋巴结清扫数目、远切端长度显著高于开腹组淋巴结清扫数目、远切端长度(P<0.05)。两组患者手术时间、术中出血量差异无统计学意义(P>0.05);NC组术后排气时间、术后进食时间显著优于开腹组(P<0.05)。NC组术后并发症总发生率为12.5%,显著低于开腹组术后并发症总发生率29.2%,差异有统计学意义(P<0.05)。

结论

规范化新辅助化疗联合常规开腹手术治疗能够增加淋巴结清扫数目、远切端长度,改善患者术后排气时间和进食时间,降低术后并发症发生率,适合临床推广应用。

Objective

To investigate the efficacy of standardized neoadjuvant chemotherapy (NC) in the treatment of low rectal cancer and its effect on surgical outcomes.

Methods

96 patients with low rectal cancer who were treated from October 2016 to October 2018 were enrolled into the study. According to the random number table. 48 cases were divided into the routine group, who received conventional open surgery, while 48 cases were divided into the NC group, who underwent standardized new adjuvant chemotherapy before open surgery. Statistical analysis were performed by using SPSS 23.0 software. Measurement data such as intraoperative and postoperative indexes were represented as (±s) and were examined by using t test. Conversion rate and postoperative complication rate were analyzed by using χ2 test. A P value of < 0.05 was considered as statistical significant difference.

Results

The number of dissected lymph nodes and the length of distal margin in the NC group were significantly better than those in the conventional group respectively (P<0.05). There were no significant difference between two groups in terms of operation time and intraoperative blood loss (P>0.05). The postoperative exhaust time and postoperative feeding time in the NC group were significantly better than those in the conventional group respectively (P<0.05). The total incidence of postoperative complications in the NC group was 12.5%, which was significantly lower than 29.2% in the conventional group, with significant difference (P<0.05).

Conclusion

Standardized neoadjuvant chemotherapy combined with conventional open surgery could increase the number of dissected lymph nodes, the length of the distal margin, and could improve the postoperative exhaust time and eating time, could reduce the incidence of postoperative complications, which is worth of clinical promotion.

表1 96例低位直肠癌患者术前不同疗法两组基线资料对比(±s)
表2 96例低位直肠癌患者不同疗法两组恶性肿瘤根治情况对比(±s)
表3 96例低位直肠癌患者不同疗法两组手术指标对比(±s)
表4 96例低位直肠癌患者不同疗法两组术后并发症发生情况对比[例(%)]
[1]
周军,徐鋆耀,阿不都斯木·艾沙,等.新辅助化疗对Ⅲ、Ⅳ期中低位直肠癌肿瘤细胞增殖能力及外周血T淋巴细胞亚群的影响[J].中华实验外科杂志,2015,32(4):684-686.
[2]
崔宗良,孙旭,宋希林,等.XELOX新辅助化疗治疗局部进展期低位直肠癌初步研究[J].中华肿瘤防治杂志,2017,24(15):1091-1093.
[3]
周明,王正兵,马建明,等.术前新辅助化疗对低位直肠癌患者的临床疗效分析[J].实用癌症杂志,2019,34(4):665-667.
[4]
邹德芳.进展期胃癌行新辅助化疗对手术风险及预后的影响[J].现代消化及介入诊疗,2016,21(1):104-106.
[5]
Mini E,Lapucci A,Perrone G,et al.RNA sequencing reveals PNN and KCNQ1OT1as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy[J].Int J Cancer,2019,145(9):2580-2593.
[6]
陈鑫.术前新辅助化疗在中低位直肠癌患者中的应用价值分析[J].中国肛肠病杂志,2019,39(2):8-9.
[7]
梁江,张云生,金雄伟,等.新辅助化疗联合手术治疗进展期胃癌的疗效观察[J/CD].中华普外科手术学杂志(电子版),2018,12(2):137-139.
[8]
任红娟,叶永生.新辅助化疗治疗宫颈癌患者的临床效果及对生存质量的影响[J].中国老年学杂志,2018,38(11):2611-2613.
[9]
Nakanishi K,Kanda M,Ito S,et al.Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset[J].Gastric Cancer,2019,22(6):1215-1225.
[10]
Shim SJ,Park W,Huh SJ,et al.The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: A multicenter, retrospective study (KROG 12-05) [J].Int J Radiat Oncol Biol Phys,2014,88(1):65-72.
[11]
韩文华,钱昆.直肠癌新辅助化疗后不同手术间隔时间对疗效及并发症的影响[J].实用癌症杂志,2018,33(9):1448-1451.
[12]
王兰.新辅助化疗治疗宫颈癌的疗效评价[J].实用药物与临床,2016,19(8):952-955.
[13]
Buisman FE,Homs MYV,Grünhagen DJ,et al.Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases-the multicenter randomized controlled PUMP trial[J].BMC Cancer,2019,19(1):327.
[14]
Yoshimatsu K,Ishibashi K,Koda K,et al.A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy[J].Surg Today,2019,49:498-506.
[15]
Morino K,Seo S,Yoh T,et al.The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma[J].Anticancer Res,2019,39(4):2155-2161.
[1] 王振宁, 杨康, 王得晨, 邹敏, 归明彬, 王雅楠, 徐明. 机器人与腹腔镜手术联合经自然腔道取标本对中低位直肠癌患者远期疗效比较[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 437-442.
[2] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[3] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[4] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[5] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[7] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[8] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[9] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[10] 刘卓, 张宗明, 张翀, 刘立民, 赵月, 齐晖. 腹腔镜手术治疗高龄急性梗阻性化脓性胆管炎患者的安全性与术式选择[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 795-800.
[11] 陈宗杰, 胡添松. 肝外伤破裂患者治疗后胆漏发生影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 836-840.
[12] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[13] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[14] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[15] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
阅读次数
全文


摘要